<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010109</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0071</org_study_id>
    <secondary_id>NCI-2021-02280</secondary_id>
    <secondary_id>2021-0071</secondary_id>
    <secondary_id>1R01HL157273-01</secondary_id>
    <nct_id>NCT05010109</nct_id>
  </id_info>
  <brief_title>Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation</brief_title>
  <official_title>Longitudinal Assessment of Cardiovascular Injury and Cardiac Fitness in LA-NSCLC Patients Receiving Model Based Personalized Chemoradiation - an Adaptive Cohort Registration Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses cardiovascular injury and cardiac fitness in patients with non-small cell&#xD;
      lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) receiving&#xD;
      model based personalized chemoradiation. The goal of this study is to learn more about the&#xD;
      risk of developing heart disease as a result of chemoradiation treatment for lung cancer.&#xD;
      Researchers also want to learn if the risk can be reduced by using a patient's individual&#xD;
      risk profile to guide cancer treatment and help protect the heart.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To longitudinally assess cardiac injury (serum biomarkers, and grade &gt;= 2 cardiac events),&#xD;
      and overall cardiac fitness (6-minute-walk test) in locally advanced (LA)-non-small cell lung&#xD;
      cancer (NSCLC) patients receiving chemoradiation.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo single photon emission computed tomography (SPECT)/computed tomography (CT)&#xD;
      with stress test and echocardiogram with strain before radiation therapy (RT), 6-8 weeks and&#xD;
      12 months after completion of RT. Patients also participate in 6 minute walk test (MWT)&#xD;
      before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after&#xD;
      completion of RT. Patients undergo blood sample collection and complete questionnaires over&#xD;
      3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and&#xD;
      24 months after completion of RT.&#xD;
&#xD;
      After completion of study treatment, patients are followed up annually for up to 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">February 23, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 23, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in level of hs-TnT &gt;= 5ng/L</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Baseline up to end or chemoradiation (CRT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade &gt;= 2 cardiovascular events</measure>
    <time_frame>Within 12-month of completion of CRT]</time_frame>
    <description>Defined by Common Terminology Criteria for Adverse Events version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall cardiac fitness</measure>
    <time_frame>Up to 24 months after CRT</time_frame>
    <description>Assessed using 6 minute walk test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5 Dimension 5 Level: Patient reported outcomes</measure>
    <time_frame>Up to 24 months after CRT</time_frame>
    <description>Score Range 0-100 (0) Worst health and (100) best health Level 1- No complaints Level 5- Worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD Anderson Symptom Inventory-Lung Cancer: Patient Report outcomes</measure>
    <time_frame>Up to 24 months after CRT</time_frame>
    <description>Score Range 0-10 (0) No symptom and (10) worst symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Locally Advanced Lung Non-Small Cell Carcinoma</condition>
  <condition>Stage III Lung Cancer AJCC v8</condition>
  <condition>Stage IIIA Lung Cancer AJCC v8</condition>
  <condition>Stage IIIB Lung Cancer AJCC v8</condition>
  <condition>Stage IIIC Lung Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Ancillary-Correlative (SPECT/CT, stress test, biospecimen)</arm_group_label>
    <description>Patients undergo SPECT/CT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>6 Minute Walk Functional Test</intervention_name>
    <description>Participate in 6 MWT</description>
    <arm_group_label>Ancillary-Correlative (SPECT/CT, stress test, biospecimen)</arm_group_label>
    <other_name>6MWT</other_name>
    <other_name>SIX MINUTE WALK</other_name>
    <other_name>SIXMW1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo blood and urine sample collection</description>
    <arm_group_label>Ancillary-Correlative (SPECT/CT, stress test, biospecimen)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Ancillary-Correlative (SPECT/CT, stress test, biospecimen)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Undergo echocardiogram</description>
    <arm_group_label>Ancillary-Correlative (SPECT/CT, stress test, biospecimen)</arm_group_label>
    <other_name>ECHO_TEST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Exercise Cardiac Stress Test</intervention_name>
    <description>Undergo stress test</description>
    <arm_group_label>Ancillary-Correlative (SPECT/CT, stress test, biospecimen)</arm_group_label>
    <other_name>ECST</other_name>
    <other_name>Exercise Stress Test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Ancillary-Correlative (SPECT/CT, stress test, biospecimen)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Ancillary-Correlative (SPECT/CT, stress test, biospecimen)</arm_group_label>
    <other_name>Medical Imaging, Single Photon Emission Computed Tomography</other_name>
    <other_name>Single Photon Emission Tomography</other_name>
    <other_name>single-photon emission computed tomography</other_name>
    <other_name>SPECT</other_name>
    <other_name>SPECT imaging</other_name>
    <other_name>SPECT SCAN</other_name>
    <other_name>SPET</other_name>
    <other_name>tomography, emission computed, single photon</other_name>
    <other_name>Tomography, Emission-Computed, Single-Photon</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Non-small cell lung cancer at the Radiation Oncology clinic or those who enrolled to&#xD;
        2020-0995&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with histologic diagnosis of non-small cell lung cancer&#xD;
&#xD;
          -  The recommended treatment is thoracic radiation therapy combined with concurrent&#xD;
             systemic therapy (chemotherapy and/or immunotherapy) with or without neoadjuvant&#xD;
             and/or adjuvant systemic therapy (chemotherapy, immunotherapy, targeted therapy)&#xD;
&#xD;
          -  &gt;= 18 years of age&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &gt;= 70&#xD;
&#xD;
          -  Willing and able to sign informed consents&#xD;
&#xD;
          -  Able and willing to perform 6minute walking test&#xD;
&#xD;
          -  Able and willing to preform required cardiac imaging examinations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to give written informed consent&#xD;
&#xD;
          -  Previous history of RT to the thorax&#xD;
&#xD;
          -  Any contraindication for cardiac imaging&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Renal failure necessitating dialysis&#xD;
&#xD;
          -  Unable to perform protocol tests&#xD;
&#xD;
          -  Contraindication for any protocol tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongxing Liao</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongxing Liao</last_name>
      <phone>832-829-5312</phone>
      <email>zliao@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Zhongxing Liao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

